Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 5:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 4,247 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Type 2 Diabetes Mellitus
Interventions: PF-05175157, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Healthy Volunteers
Interventions: TAK-915 suspension, Midazolam, Placebo, TAK-915 tablet; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Emotional Dysregulation
Interventions: N-Acetyl Cysteine (NAC), Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 12 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts • Cambridge, Massachusetts

Conditions: Cocaine Dependency
Interventions: CPP-115, Placebo; Drug
Lead sponsor: Catalyst Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Mild Cognitive Impairment
Interventions: Grape Powder, Placebo Powder; Dietary Supplement
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 65 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Dyspepsia
Interventions: Zypan, Placebo Comparator; Dietary Supplement
Lead sponsor: National University of Natural Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hyperlipidemia
Interventions: SLx-4090, Placebo, Statin; Drug · Other
Lead sponsor: Response Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 19
States / cities: Birmingham, Alabama • Tempe, Arizona • Tucson, Arizona + 14 more

Conditions: Alzheimer's Disease
Interventions: VP4896; Drug
Lead sponsor: Voyager Pharmaceutical Corporation; Industry
Eligibility: 60 Years and older
Enrollment: 555 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 55
States / cities: Peoria, Arizona • Tucson, Arizona • Fresno, California + 49 more

Conditions: MAC Lung Disease, Treatment Refractory MAC Lung Disease
Interventions: Epetraborole, Placebo; Drug
Lead sponsor: AN2 Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 49
States / cities: Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 39 more

Conditions: Respiratory Distress Syndrome
Interventions: Lucinactant delivered via investigational delivery device, nCPAP; Drug
Lead sponsor: Windtree Therapeutics; Industry
Eligibility: 26 Weeks to 32 Weeks
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 22
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 18 more

Conditions: HIV Infections, Lipodystrophy, Hyperinsulinemia
Interventions: Metformin hydrochloride, Rosiglitazone maleate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 34
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 20 more

Conditions: Depressive Episodes, Bipolar I Depression
Interventions: SEP-4199 CR 200 mg, SEP-4199 CR 400 mg, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 34
States / cities: Huntsville, Alabama • Bryant, Arkansas • Anaheim, California + 30 more

Conditions: Malaria
Interventions: DM1157, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pain, Postoperative, Arthroplasty Complications
Interventions: Ketamine; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Neuropathic Pain
Interventions: OK-101 0.05%, OK-101 0.1%, Placebo; Drug
Lead sponsor: Okyo Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypercortisolism
Interventions: Relacorilant, Placebo; Drug · Other
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 22
States / cities: Birmingham, Alabama • Stanford, California • Torrance, California + 19 more

Conditions: Renal Cell Carcinoma, Metastatic
Interventions: Intuvax (INN: ilixadencel), Sunitinib; Biological · Drug
Lead sponsor: Mendus; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 5
States / cities: Chicago, Illinois • Iowa City, Iowa • Saint Paul, Minnesota + 1 more

Conditions: Nocturia
Interventions: VA106483; Drug
Lead sponsor: Vantia Ltd; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 19
States / cities: Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 16 more

Conditions: Inappropriate Prescribing
Interventions: Z-drug Default Quantity, Redirection + Accountable Justification; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Actinic Keratosis
Interventions: Diclofenac sodium, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 30
States / cities: Mesa, Arizona • Tucson, Arizona • Fremont, California + 23 more

Conditions: Immune Thrombocytopenia
Interventions: Avatrombopag, Placebo; Drug
Lead sponsor: Sobi, Inc.; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 21
States / cities: Phoenix, Arizona • Long Beach, California • Orange, California + 18 more

Conditions: Acne Vulgaris
Interventions: GDC 268 Lotion, Clindamycin Phosphate Lotion 1%, GDC Vehicle Lotion; Drug
Lead sponsor: Balmoral Medical company; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 1,236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 34
States / cities: Fort Smith, Arkansas • Rogers, Arkansas • Fountain Valley, California + 31 more

Conditions: Nonexudative Age-related Macular Degeneration
Interventions: MC-1101, Placebo; Drug
Lead sponsor: MacuCLEAR, Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Artesia, California

Conditions: Deep Dental Caries
Interventions: Indirect Pulp capping-Resin-modified calcium silicate - TheraCal, Indirect Pulp capping-Calcium hydroxide - Dycal, Indirect Pulp capping-Resin-based dentin bonding agent, Direct Pulp capping-Resin-modified calcium silicate - TheraCal, Direct Pulp capping-Calcium hydroxide - Dycal; Procedure
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 64 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin

Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study

The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation

A Safety, Tolerability and Pharmacokinetic Study of CPP-115

Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance Over 1 Year

Zypan Functional Dyspepsia

Comparison of SLx-4090 Combined With Statin Therapy Versus Statin Alone in Reducing LDL-C in Patients With Hyperlipidemia

ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)

Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age

Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities

A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.

Safety and Pharmacokinetics Study of DM1157 to Treat Malaria

Intraoperative Ketamine for Patients Undergoing Total Joint Arthroplasty

The Study Assessing the Safety and Efficacy of OK-101 Treatment in Subjects With Neuropathic Corneal Pain

A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas

Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)

Efficacy Study of VA106483 in Males With Nocturia.

The Study in Outpatient Medicine Using Nudges to Improve Sleep

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp

Avatrombopag for the Treatment of Thrombocytopenia in Pediatric Subjects With Immune Thrombocytopenia for ≥6 Months

Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris

Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration

Clinical Comparison of Vital Pulp Capping Restorative Protocols